Monoamine Oxidase B in Renal Cell Carcinoma

Abstract

BackgroundStudies on monoamine oxidase B (MAO-B) expression in renal cell carcinoma (RCC) are lacking. This study focused on the immunohistochemical evaluation of MAO-B in RCC.Material/MethodsSixty-three RCC samples were compared on basic clinical and histopathological parameters, including histopathological type and tumor grade. RCC samples were divided according to the histopathological type into 2 groups: conventional type (51 samples) and other types (12 samples). For MAO-B detection, a standard immunohistochemical procedure was employed.ResultsIn healthy kidney samples, MAO-B was detected predominantly in tubules. Fifty-two cancer tissue samples were MAO-B negative and 11 tissue samples were MAO-B low positive. Enzymes were detected only in the cytoplasm. We did not find any significant correlation between the percentage of positive MAO-B specimens and nuclear grade. Additionally, Fisher’s test did not reveal any difference in numbers of positive and negative MAO-B samples between the 2 RCC types (P>0.05).ConclusionsFrom our results, it was clear that MAO-B expression played no significant role in stimulation of renal cancer development. We found that MAO-B occurred only in 19% of kidney tumors and that the positivity of protein expression was low. Moreover, it seems that the disappearance of this enzyme in RCC is a consequence of replacement of healthy tissue by cancer cells. On the other hand, one can assume that the loss of MAO-B expression could be associated with severe pathological processes in the kidney.

Loss of SETD2‐mediated downregulation of intracellular and exosomal miRNA‐10b determines MAPK pathway activation and multidrug resistance in renal cancer

“…Apart from surgery, other current therapies slightly improve the overall survival in patients with advanced disease. Moreover, renal cancer is notorious for multidrug resistance (MDR) and most patients being insensitive to chemotherapeutic drugs 3–7 …”

The clinical value and potential molecular mechanism of the downregulation of MAOA in hepatocellular carcinoma tissues

“…Recently, the overexpression of MAOA has been reported in various cancers, such as prostate cancer, 19,20 renal cell carcinoma, 21 classical Hodgkin lymphomas, 22 and glioma 23 . Conversely, other studies have found a downregulation trend of MAOA in several cancers 24,25 .…”